Skip to main content
Journal of Ophthalmic Inflammation and Infection

Table 5 Recurrences and medications

From: Clinical characterization of patients with HLA-B27-associated uveitis and evaluation of the impact of systemic treatment on the recurrence rate: a cross-sectional study

Medication

Frequency of use

P-value

Oral Corticosteroid

8/33 (24.2%)

P = 0.215

SC Corticosteroid

5/33 (15.2%)

P = 1

Methotrexate

9/33 (27.2%)

P = 0.181

Azathioprine

1/33 (3.0%)

P = 1

Sulfasalazine

2/33 (6.1%)

P = 1

Biologics

13/33 (39.4%)

P = 0.144

Rituximab

1/33 (3%)

P = 1

Infliximab

4/33 (12.1%)

P = 1

Etanercept

2/33 (6.1%)

P = 1

Adalimumab

4/33 (12.1%)

P = 0.527

Certolizumab

2/33 (6.1%)

P = 1

Golimumab

2/33 (6.1%)

P = 1

MTX + ADA

7/33 (21.2%)

P = 0.561

  1. Legend: The number of patients who took each medication and had at least one recurrence during follow-up was expressed as a proportion (patients who took the medication and had a recurrence/total patients with recurrences) and percentage. A Fisher Exact test was performed to assess each association statistically. SC Subconjunctival, MTX + ADA Combined therapy of methotrexate and adalimumab
Back to article page